Pfizer CEO Wants To See Annual COVID Shots

The CEO of Pfizer gave a public statement over the weekend that he hopes people worldwide will receive annual shots of the COVID-19 vaccine that his company makes billions from producing. Albert Bourla’s comments came as booster shots are central to global vaccinations campaigns.

A reporter asked Bourla if he believed COVID vaccine booster shots would become routine on a repeating cycle of every four or five months. He responded by saying that he “hoped to see people everywhere taking annual boosters of the vaccine jab.”

He said that shots every few months would not be “a good scenario” but expressed hope for a Pfizer vaccine that “you will have to do” once per year. He justified that hope by saying it is “easier to convince” people that an annual booster is needed rather than a semi-annual shot.

It would be “easier to remember,” according to Bourla, to get a shot once a year in perpetuity. He described it as an “excellent circumstance” for public health. Pfizer is developing a vaccine for the omicron version and other types.

Last November, Pfizer’s third-quarter earnings report indicated estimated total revenue through 2021 from its COVID-19 vaccine of $36 billion. The company also reported a net income of around $8.1 billion for the same period, up from $1.5 billion in the same period in 2020.

Last week, Joe Biden’s Director for the Centers for Disease Control and Prevention, Rochelle Walensky, said that the CDC is now working to change the meaning of “fully vaccinated” to include a still undisclosed number of booster shots.

She said that the CDC wants to “pivot the language” to ensure all Americans are “up to date” with their vaccinations. She went on to say that if a person is eligible for a booster and has not received it, they are not “up to date” and presumably no longer fully vaccinated as the CDC defines that term.

There remains no indication of how many boosters will eventually be deemed necessary or how often they will be needed to be received. Accordingly, there is no known limit to the amount of money the federal government will pay to Pfizer to generate the experimental medication.